Results 191 to 200 of about 32,386 (229)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2003
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Bornadata, Bain, Melanie, Brazil
openaire +3 more sources
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Bornadata, Bain, Melanie, Brazil
openaire +3 more sources
American Journal of Clinical Dermatology, 2009
Adalimumab is a recombinant, human, IgG1 monoclonal antibody specific for tumor necrosis factor. The clinical efficacy and safety of adalimumab (40 mg administered subcutaneously every other week) in patients with moderate-to-severe chronic plaque psoriasis have been demonstrated in several randomized, double-blind clinical trials, including the ...
Katherine F, Croom, Paul L, McCormack
openaire +3 more sources
Adalimumab is a recombinant, human, IgG1 monoclonal antibody specific for tumor necrosis factor. The clinical efficacy and safety of adalimumab (40 mg administered subcutaneously every other week) in patients with moderate-to-severe chronic plaque psoriasis have been demonstrated in several randomized, double-blind clinical trials, including the ...
Katherine F, Croom, Paul L, McCormack
openaire +3 more sources
BioDrugs, 2007
Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that ...
Greg L, Plosker +1 more
openaire +3 more sources
Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that ...
Greg L, Plosker +1 more
openaire +3 more sources
Reactions Weekly, 2013
Adalimumab - biološka terapija u liječenju vulgarne ...
openaire +2 more sources
Adalimumab - biološka terapija u liječenju vulgarne ...
openaire +2 more sources